<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287792</url>
  </required_header>
  <id_info>
    <org_study_id>AOM13549</org_study_id>
    <nct_id>NCT02287792</nct_id>
  </id_info>
  <brief_title>18-FDG PET/CT Imaging and Clinical Decisions in Infective Endocarditis</brief_title>
  <acronym>TEPvENDO</acronym>
  <official_title>Effect of 18-FDG PET/CT Imaging on Clinical Decision Making During the Acute Phase of Infective Endocarditis: a Multicenter Prospective Impact Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact of 18-FDG positron emission tomography&#xD;
      (PET)/computed tomography (CT) imaging in the management of patients with suspected or proven&#xD;
      IE in detecting cardiac valve damages and other extracardiac complications. The study will&#xD;
      evaluate whether this procedure can change the clinical decisions (treatments, valve surgery,&#xD;
      patients' overall care) and modify the diagnosis of IE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:&#xD;
&#xD;
      Infective endocarditis (IE) is a rare disease, often difficult to diagnose with a high&#xD;
      mortality rate. Extra-cardiac manifestations, which can occur in 30 to 80% of cases, impact&#xD;
      the outcome of the disease. Identifying these manifestations may help confirm an uncertain&#xD;
      diagnosis and optimize patients' management.&#xD;
&#xD;
      18-FDG PET/CT imaging, widely used for cancer staging, may also detect hyper-metabolic areas&#xD;
      related to extracardiac infectious complications of IE. It provides the opportunity to detect&#xD;
      all extracardiac IE infectious complications through a single examination. The impact of&#xD;
      18-FDG PET/CT imaging on the management of IE has yet to be completely evaluated.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      18-FDG PET/CT implementation could result in both shortening of the initial diagnostic&#xD;
      work-up of IE and therapeutic optimization.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To evaluate the impact of 18-FDG PET/CT on patients' management, as measured by changes in IE&#xD;
      therapeutic plans.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To evaluate the impact of 18-FDG PET/CT on the Duke-Li criteria for IE diagnosis&#xD;
&#xD;
        -  To evaluate the performance of 18-FDG PET/CT in detecting valve damages and extracardiac&#xD;
           complications induced by the IE&#xD;
&#xD;
        -  To evaluate whether 18-FDG PET/CT may help identify the infection's portal of entry&#xD;
&#xD;
        -  To evaluate whether the detection of extracardiac complications by FDG PET/CT is&#xD;
           associated with the 6-months survival rate&#xD;
&#xD;
        -  To identify clinical and biological determinants of extracardiac IE localizations and&#xD;
           prognosis&#xD;
&#xD;
        -  To determine the inter-reader interpretation of the18-FDG PET/CT results and the&#xD;
           reproducibility in preparation and acquisition method&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 17, 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a change in IE therapeutic plan</measure>
    <time_frame>7 days</time_frame>
    <description>at least one modification in antimicrobial or anticoagulant therapy (types, route, dose, number, duration, indication…) or any modification of surgery (type, timing, indications…)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Duke-Li classification modifications</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients with change in diagnostic classification of IE (definite, possible, excluded) according to the Duke-Li classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performances of 18-FDG PET/CT in detection of IE localization as compared to other usual procedures</measure>
    <time_frame>6 months</time_frame>
    <description>1/ in detecting valve damages and extracardiac complications and 2/ in identify the portal of entry of IE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month mortality rate</measure>
    <time_frame>6 months</time_frame>
    <description>number of dead patients 6 months after inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determinants of change in therapeutic plan as defined in primary outcome</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical and biological determinants of therapeutic changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18-FDG PET/CT inter-reader reproducibility</measure>
    <time_frame>6 months</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Infective Endocarditis</condition>
  <arm_group>
    <arm_group_label>18-FDG PET/CT scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will undergo a whole body PET/CT scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>18-FDG PET/CT scan</intervention_name>
    <description>Whole body 18-FDG PET/CT to assess cardiac and extracardiac complications in infective endocarditis</description>
    <arm_group_label>18-FDG PET/CT scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects aged ≥ 18 years&#xD;
&#xD;
          2. Presenting IE &quot;Duke-Li definite - Duke-Li possible&quot; or strong suspicion of IE &quot;Duke-Li&#xD;
             not definite or possible, with initiation of IE antibiotic therapy&quot;.&#xD;
&#xD;
          3. Transthoracic or transesophageal ultrasound performed.&#xD;
&#xD;
          4. A stable clinical condition which does not require immediate surgery or contraindicate&#xD;
             patient mobilization&#xD;
&#xD;
          5. Absence of cardiac surgery for the current IE episode&#xD;
&#xD;
          6. Covered by the French health insurance system&#xD;
&#xD;
          7. Having given and signed the written study informed consent to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient having already had a 18-FDG PET/CT in the current episode&#xD;
&#xD;
          2. Contraindication to perform a 18-FDG PET/CT&#xD;
&#xD;
          3. Early prosthetic valve IE (cardiac surgery within last 2 months)&#xD;
&#xD;
          4. Inability to understand the information form&#xD;
&#xD;
          5. Pregnant or lactating woman.&#xD;
&#xD;
          6. Cardiac surgery between inclusion and 18-FDG PET/CT&#xD;
&#xD;
          7. Participation to any clinical trial including 18-FDG PET/CT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Duval, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bichat Claude Bernard Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>October 31, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infective endocarditis</keyword>
  <keyword>18-FDG PET/CT</keyword>
  <keyword>Impact</keyword>
  <keyword>Patient's management</keyword>
  <keyword>Diagnostic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis, Bacterial</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

